BioCentury | Jul 3, 2020
Finance

On heels of $100M raise, Annexon joins burgeoning IPO queue

Two days after raising $100 million in a series D round heavy with crossover investors, Annexon has filed to go public on NASDAQ. The filing adds to a burgeoning IPO queue and caps another busy...
BioCentury | May 28, 2019
Distillery Therapeutics

Split intein-based gene therapies for two types of congenital blindness

...therapies in porcine or other large animal models of the retinal diseases. TARGET/MARKER/PATHWAY: ATP-binding cassette sub-family A member 4 (ABCA4; ABCR...
...Pozzuoli, Italy; University of Naples Federico II, Naples, Italy email: auricchio@tigem.it Sandi Wong University of Naples Federico II ATP-binding cassette sub-family A member 4 (ABCA4) (ABCR) Centrosomal...
BioCentury | May 6, 2019
Financial News

May 6 Financial Quick Takes: Athenex, Spiral

Athenex raises $100M to advance Oraxol Looking to fund commercialization activities for Oraxol and advance its oncology pipeline and actinic keratosis therapy, Athenex Inc. (NASDAQ:ATNX) raised $100 million in a private placement through the sale...
BioCentury | Feb 8, 2019
Company News

Sanofi seeking partner to develop Oxford BioMedica's ophthalmology gene therapies

...type 1b. Sanofi is in discussions with potential external partners, according to Oxford. ABCA4 (ABCR) - ATP-binding cassette sub-family A member 4...
...LSE:OXB), Oxford, U.K. Sanofi (Euronext:SAN; NASDAQ:SNY), Paris, France Business: Ophthalmology Shannon Lehnbeuter StarGen (SAR422459) UshStat (SAR 421869) Oxford BioMedica plc Sanofi ATP-binding cassette sub-family A member 4 (ABCA4) (ABCR) Myosin...
BioCentury | Jul 11, 2018
Translation in Brief

Poisoning the stromal chalice

A study published in the Journal of Clinical Investigation suggests antibody-drug conjugates targeting the tumor stroma could treat cancers by co-opting a stromal mechanism to feed cytotoxic drugs to the surrounding tumor cells. Tumor-associated stroma,...
BioCentury | Jun 8, 2018
Company News

Opthotech gains gene therapy for ophran vision-loss disease

...to centrosomal protein 290kDa (CEP290) mutations; and autosomal recessive Stargardt disease due to ATP-binding cassette sub-family A member 4 (ABCA4; ABCR...
...NASDAQ:OPHT), New York, N.Y. Business: Ophthalmic, Gene therapy Jennie Walters Zimura, avacincaptad pegol Ophthotech Corp. University of Florida University of Pennsylvania ATP-binding cassette sub-family A member 4 (ABCA4) (ABCR) Centrosomal...
BioCentury | Jun 7, 2018
Company News

Ophthotech gains gene therapy for orphan vision-loss disease

...to centrosomal protein 290kDa (CEP290) mutations; and autosomal recessive Stargardt disease due to ATP-binding cassette sub-family A member 4 (ABCA4; ABCR...
BioCentury | May 5, 2018
Product Development

Rebuilding Biogen’s brain

Biogen Inc. is still a long way from a full rebuild of its pipeline, with an Alzheimer’s disease-laden Phase III lineup that needs to diversify. But there’s progress in the early- to mid-stage programs where...
BioCentury | Apr 17, 2018
Distillery Techniques

Disease models; drug properties

TECHNOLOGY: 3-D models; pharmacokinetics/pharmacodynamics 3-D human intestinal organoids could be used to test the PK properties of drug compounds. The organoids are generated by culturing human induced pluripotent stem (iPS) cells in a medium containing...
BioCentury | Feb 9, 2018
Clinical News

Biogen discontinuing natalizumab for stroke after Phase IIb miss

Biogen Inc. (NASDAQ:BIIB) discontinued development of natalizumab to treat acute ischemic stroke after the drug missed the primary and secondary endpoints in the Phase IIb ACTION 2 trial in the indication. Biogen markets natalizumab, a...
Items per page:
1 - 10 of 83